title: [Effect of prodigiozan on immune reactivity in patients with steroid-dependent bronchial asthma].
abstract: An optimum scheme of prodigiosan therapy was developed for patients with steroid-dependent bronchial asthma taking account of the hormonal and immunological status. First the drug was administered at a dose of 0.1 ml of 0.005% solution, then in 3-4 days the dose was increased (in good tolerance) up to 0.2-0.4-0.8-1.0 ml. After the first administration of the drug at a dose exceeding 0.1 ml herpes virus could be activated in the body. Course therapy producing a stimulating effect on the immune system, inhibited the occurrence of autoimmune manifestations, prolonged bronchial asthma remission, permitted the reduction of retention of a maintenance dose of glucocorticoids.
authors.forename: A A
authors.initials: AA
authors.lastname: Andriukin
authors.forename: V F
authors.initials: VF
authors.lastname: Marinin
authors.forename: E G
authors.initials: EG
authors.lastname: Nastiukova
authors.forename: L N
authors.initials: LN
authors.lastname: Dudkina
authors.forename: N Iu
authors.initials: NIu
authors.lastname: Niaĭkina
mesh_terms: D000328:Adult; D000937:Antigen-Antibody Reactions / Q000187:drug effects*; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology; D004305:Dose-Response Relationship, Drug; D005260:Female; D005938:Glucocorticoids; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007111:Immunity, Cellular / Q000187:drug effects; D007962:Leukocytes / Q000187:drug effects / Q000276:immunology; D008297:Male; D011135:Polysaccharides, Bacterial / Q000627:therapeutic use*; D011354:Prodigiozan / Q000627:therapeutic use*; D019966:Substance-Related Disorders / Q000188:drug therapy* / Q000276:immunology; D013997:Time Factors
chemical_list: D005938:Glucocorticoids; D011135:Polysaccharides, Bacterial; D011354:Prodigiozan
vernacular_title: Vliianie prodigiozana na immunnuiu reaktivnost' bol'nykh steroidzavisimoĭ bronkhial'noĭ astmoĭ.